How Trump's Section 301 probe could impact India's trade
What's the story
The US government has launched a trade investigation under Section 301 of the Trade Act of 1974, targeting India and 15 other countries. The move follows the recent US Supreme Court's decision to strike down Trump's "reciprocal tariff" policy. The investigation could potentially lead to new tariffs on India and other nations. But what exactly is a Section 301 probe?
Trade enforcement
Meaning of Section 301 of the US Trade Act
Section 301 of the US Trade Act of 1974 is a powerful tool that allows the US to take action against foreign policies considered harmful to American commerce. The law empowers the Office of the United States Trade Representative (USTR) to investigate policies, regulations, and barriers that could harm American businesses or disadvantage US exports.
Probe procedure
Investigation process and outcomes
When an investigation is initiated, the USTR collects evidence through various means, including public comments and the concerned country. These investigations usually take months and are necessary for the US president to impose tariffs on imports from certain countries found to be engaging in unfair trade practices. If proven guilty, the US could impose tariffs or import restrictions under this law.
Target nations
Countries under investigation
Along with India, other countries being investigated include China, the European Union, South Korea, and Mexico. Japan, Taiwan, Vietnam, Singapore, Switzerland, Norway Indonesia Malaysia Cambodia Bangladesh and Thailand are also on the list. The investigations will focus on economies that allegedly exhibit structural excess capacity and production in various manufacturing sectors through larger persistent trade surpluses or underutilized/unused capacity.
Trade implications
Potential impact on Indian exports to the US
India's inclusion in the investigation list highlights long-standing concerns over its trade policies. These include high tariffs, local sourcing requirements, and price controls in the pharmaceutical sector. If violations are found, a number of Indian exports could be subject to heavy tariffs. For example, pharmaceuticals—a key export to the US—could face higher costs or stricter regulations while IT hardware/electronics may become less competitive due to potential new duties.